S2-E16 -- Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment

Send us a text

Mazen Noureddin joins the Surfers to discuss his work determining cost effectiveness of Non-Invasive Testing in Type 2 diabetics and the broader population. The discussion shifts to considering broader treatment issues. 

Dr. Noureddin starts the discussion by providing a history of cost-effectiveness research in NASH and NAFLD. At a population level, biopsy turns out never to be cost-effective while less expensive tests almost always are. As the group brainstormed implications and new questions, they touched on theories on how cost-effectiveness for F3 and F2 patients might differ, and even how chronic therapies and sequential use of specific medicines might reflect cost-effectiveness issues. An enlightening way to think about testing and treatment today, and how these will evolve over time.